Damora Therapeutics Balance Sheet
NASDAQ: DMRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Damora Therapeutics financial position
At the end of fiscal 2025, Damora Therapeutics reported total assets of $260.5 million, up 1420.7% from a year earlier against total liabilities of $20.1 million. Shareholders' equity stood at $240.4 million, or 92.3% of assets. The company held $257.6 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 12.98, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Damora Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 257.62M | 14.18M | 21.46M | 32.79M | 62.56M | 163.58M | 11.29M |
| Short-Term Investments | — | — | 11.69M | 27.44M | 37.63M | — | — |
| Total Current Assets | 260.42M | 16.84M | 36.77M | 63.91M | 110.10M | 169.29M | 56.08M |
| Property, Plant & Equipment | 36.00K | 57.00K | 78.00K | 357.00K | 203.00K | — | — |
| Long-Term Investments | — | — | — | 5.83M | 9.05M | — | — |
| Total Assets | 260.53M | 17.13M | 38.23M | 73.19M | 122.22M | 171.60M | 56.61M |
| Accounts Payable | 444.00K | 377.00K | 1.70M | 3.35M | 1.53M | 2.85M | 3.33M |
| Total Current Liabilities | 20.07M | 1.20M | 5.83M | 11.11M | 4.54M | 5.57M | 7.93M |
| Total Liabilities | 20.15M | 1.30M | 5.90M | 11.44M | 4.99M | 6.11M | 8.14M |
| Shareholders' Equity | 240.38M | 15.83M | 32.33M | 61.75M | 117.22M | 165.49M | -71.15M |
| Retained Earnings | -487.36M | -277.52M | -256.08M | -217.74M | -156.11M | -104.36M | -69.52M |
| Net Cash (Debt) | 257.62M | 14.18M | 33.15M | 60.22M | 100.19M | 163.58M | 11.29M |
| Shares Outstanding | 1.60M | 1.32M | 1.08M | 25.65M | 25.26M | 25.26M | 259.97K |
This table shows 7 annual periods of Damora Therapeutics's balance sheet, from FY 2025 back to FY 2019, across 13 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow DMRA's reporting calendar. What is a balance sheet?